Abstract
Alzheimer’s disease (AD) is influenced by a variety of modifiable risk factors, including a person’s dietary habits. While the ketogenic diet (KD) holds promise in reducing metabolic risks and potentially affecting AD progression, only a few studies have explored KD’s metabolic impact, especially on blood and cerebrospinal fluid (CSF). Our study involved participants at risk for AD, either cognitively normal or with mild cognitive impairment. The participants consumed both a modified Mediterranean-ketogenic diet (MMKD) and the American Heart Association diet (AHAD) for 6 weeks each, separated by a 6-week washout period. We employed nuclear magnetic resonance (NMR)-based metabolomics to profile serum and CSF and metagenomics profiling on fecal samples. While the AHAD induced no notable metabolic changes, MMKD led to significant alterations in both serum and CSF. These changes included improved modifiable risk factors, like increased HDL-C and reduced BMI, reversed serum metabolic disturbances linked to AD such as a microbiome-mediated increase in valine levels, and a reduction in systemic inflammation. Additionally, the MMKD was linked to increased amino acid levels in the CSF, a breakdown of branched-chain amino acids (BCAAs), and decreased valine levels. Importantly, we observed a strong correlation between metabolic changes in the CSF and serum, suggesting a systemic regulation of metabolism. Our findings highlight that MMKD can improve AD-related risk factors, reverse some metabolic disturbances associated with AD, and align metabolic changes across the blood-CSF barrier.
Competing Interest Statement
Dr. Krumsiek holds equity in Chymia LLC and iollo, owns intellectual property in PsyProtix, and serves as an advisor for celeste. Dr. Annalise Schweickart is a co-founder of celeste. Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix.
Clinical Trial
NCT02984540
Funding Statement
Samples were provided by Wake Forest Alzheimer's Disease Research Center (WFADRC) supported by (P30AG049638) and associated laboratory staff, the Hartman Family Foundation, and the Roena B. Kulynych Center for Memory and Cognition Research. We would like to acknowledge the contributions of the Wake Forest Clinical and Translational Science Institute which is supported by the National Center for Advancing Translational Sciences (NCATS) through National Institutes of Health grant UL1TR001420. Additional support was provided by the Swedish Research Council and Swedish State Support for Clinical Research (ALFGBG) and laboratory technicians at Sahlgrenska University Hospital, Molndal, Sweden. Metabolomics data is provided by the Alzheimer's Gut Microbiome Project (AGMP) or the Alzheimer's Disease Metabolomics Consortium (ADMC) funded wholly or in part by the following grants and supplements thereto: NIA R01AG046171, RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744 and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such, the investigators within the AGMP and the ADMC, not listed specifically in this publication's author's list, provided data along with its pre-processing and prepared it for analysis, but did not participate in analysis or writing of this manuscript. A listing of AGMP Investigators can be found at https://alzheimergut.org/meet-the-team/. A complete listing of ADMC investigators can be found at: https://sites.duke.edu/adnimetab/team/. Drs. Krumsiek and Batra are supported by the National Institute of Aging of the National Institutes of Health under awards U19AG063744, R01AG069901-01 and Alzheimer's association award AARFD-22-974775.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Wake Forest Institutional Review Board of Wake Forest University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Samples were provided by Wake Forest Alzheimer's Disease Research Center. Clinical data can be requested from the National Alzheimer’s Coordinating Center.
